Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C22H29FO5) intratympanic injection

xlomafota13 shared this article with you from Inoreader Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>) intratympanic injection Via Experimental and therapeutic medicine Exp Ther Med. 2022 Feb;23(2):125. doi: 10.3892/etm.2021.11048. Epub 2021 Dec 7. ABSTRACT Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-acute symptomatology. The aim of the present study was to assess 285 patients with SOM diagnosed within a two-year span. The etiology and pathology of hearing loss in patients with different age groups were examined. The importance of a clinical examination and tympanometry was emphasized as absolutely necessary for a correct diagnosis. Treatment targeted Eustachian Tube permeabilization for satisfactory long-term middle ear aeration. Nasal drops with vasoconstrictor drugs (phenylephrine) and disinfectant (colloidal silver 1%) were commonly used, but some patients also benefitted from dexamethasone intratympanic injection. Patients were evaluated at the end of the treatment and follow-up occurred at one month, one year and three years later. PMID:34970348 | PMC:PMC8713185 | DOI:10.3892/etm.2021.11048 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.